G. W. Sledge

4.5k total citations
46 papers, 1.3k citations indexed

About

G. W. Sledge is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, G. W. Sledge has authored 46 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in G. W. Sledge's work include Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (11 papers) and HER2/EGFR in Cancer Research (11 papers). G. W. Sledge is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (11 papers) and HER2/EGFR in Cancer Research (11 papers). G. W. Sledge collaborates with scholars based in United States, United Kingdom and Canada. G. W. Sledge's co-authors include Elisabeth A. Bone, R. Fife, Kathy D. Miller, Robert Timmerman, Jiazhou Shen, Lena Haney, Maura N. Dickler, Tess D. Weathers, Joseph A. Sparano and Nancy E. Davidson and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

G. W. Sledge

43 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. W. Sledge United States 14 859 527 336 324 162 46 1.3k
Alejandra Perez United States 12 842 1.0× 588 1.1× 611 1.8× 493 1.5× 138 0.9× 30 1.6k
Sònia Pernas Spain 20 1.1k 1.3× 545 1.0× 447 1.3× 413 1.3× 129 0.8× 109 1.6k
Ying Fan China 23 1.1k 1.3× 697 1.3× 513 1.5× 542 1.7× 125 0.8× 120 1.7k
Angela Espósito Italy 21 1.1k 1.3× 762 1.4× 396 1.2× 404 1.2× 148 0.9× 56 1.6k
Linnea Chap United States 13 1.0k 1.2× 417 0.8× 367 1.1× 662 2.0× 85 0.5× 28 1.7k
Serafín Morales Spain 16 1.2k 1.3× 494 0.9× 574 1.7× 362 1.1× 69 0.4× 134 1.6k
Zhenzhou Shen China 20 689 0.8× 574 1.1× 202 0.6× 551 1.7× 249 1.5× 54 1.5k
Eugen Ruckhaeberle Germany 15 863 1.0× 705 1.3× 223 0.7× 348 1.1× 211 1.3× 20 1.5k
Angel Rodriguez United States 21 770 0.9× 609 1.2× 235 0.7× 494 1.5× 181 1.1× 49 1.4k
Antonio Marchetti Italy 23 878 1.0× 594 1.1× 715 2.1× 929 2.9× 177 1.1× 39 1.8k

Countries citing papers authored by G. W. Sledge

Since Specialization
Citations

This map shows the geographic impact of G. W. Sledge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. W. Sledge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. W. Sledge more than expected).

Fields of papers citing papers by G. W. Sledge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. W. Sledge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. W. Sledge. The network helps show where G. W. Sledge may publish in the future.

Co-authorship network of co-authors of G. W. Sledge

This figure shows the co-authorship network connecting the top 25 collaborators of G. W. Sledge. A scholar is included among the top collaborators of G. W. Sledge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. W. Sledge. G. W. Sledge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Graff, Stephanie L., Andrew Elliott, Estelamari Rodríguez, et al.. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open. 8(1). 101404–101404. 3 indexed citations
2.
Solin, Lawrence J., Robert P. Gray, Frederick L. Baehner, et al.. (2013). A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. JNCI Journal of the National Cancer Institute. 105(10). 701–710. 335 indexed citations
3.
4.
Badve, Sunil, et al.. (2011). PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146.. Journal of Clinical Oncology. 29(15_suppl). TPS130–TPS130. 3 indexed citations
5.
Hurwitz, Herbert I., Pamela S. Douglas, G. W. Sledge, et al.. (2010). Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).. Journal of Clinical Oncology. 28(15_suppl). 3039–3039. 39 indexed citations
6.
Duchnowska, Renata, Jacek Jassem, Mangesh A. Thorat, et al.. (2009). Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC).. Cancer Research. 69(2_Supplement). 2028–2028. 1 indexed citations
7.
8.
Gray, Robert P., Barrett H. Childs, Tara Maddala, et al.. (2008). HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197. Journal of Clinical Oncology. 26(15_suppl). 22009–22009. 4 indexed citations
9.
Goldstein, Lori J., Robert J. Gray, Roberto Bugarini, et al.. (2008). Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. Journal of Clinical Oncology. 26(15_suppl). 557–557. 1 indexed citations
10.
O’Shaughnessy, J., K. L. Blackwell, Harold J. Burstein, et al.. (2008). A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Journal of Clinical Oncology. 26(15_suppl). 1015–1015. 109 indexed citations
11.
Baselga, José, Federico Rojo, Andy Ryan, et al.. (2005). Pharmacodynamic assessment of ZD6474 (ZACTIMA (TM)) in the skin of patients with previously treated metastatic breast cancer.. Clinical Cancer Research. 11. 1 indexed citations
12.
Salazar, Jaime de, Fikri İçlı, Tadeusz Pieńkowski, et al.. (2005). ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer. Journal of Clinical Oncology. 23(16_suppl). 576–576. 11 indexed citations
13.
Miller, Kathy D., Tess D. Weathers, Lena Haney, et al.. (2003). Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Annals of Oncology. 14(7). 1072–1077. 193 indexed citations
14.
Sledge, G. W., et al.. (2001). Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198). Breast Cancer Research and Treatment. 69(3). 4 indexed citations
15.
Gianni, Luca, P Dombernowsky, G. W. Sledge, et al.. (2001). Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer. Annals of Oncology. 12(8). 1065–1071. 63 indexed citations
16.
Miller, Kathy D., et al.. (2001). Occult central nervous system (CNS) involvement in patients (pts.) with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. 69(3). 6 indexed citations
17.
Singhal, Radhey L., et al.. (1995). Quercetin Down-Regulates Signal Transduction in Human Breast Carcinoma Cells. Biochemical and Biophysical Research Communications. 208(1). 425–431. 104 indexed citations
18.
Sledge, G. W., et al.. (1995). Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic Mice. JNCI Journal of the National Cancer Institute. 87(20). 1546–1551. 158 indexed citations
19.
Oláh, Edith, et al.. (1994). Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: Schedule-dependence. Life Sciences. 54(24). PL431–PL435. 13 indexed citations
20.
Sledge, G. W.. (1990). Chemotherapy-induced nausea and vomiting. Current Opinion in Oncology. 2(5). 909–914. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alejandra Perez Breakdown of academic impact, for papers by Sònia Pernas Breakdown of academic impact, for papers by Ying Fan Breakdown of academic impact, for papers by Angela Espósito Breakdown of academic impact, for papers by Linnea Chap Breakdown of academic impact, for papers by Serafín Morales Breakdown of academic impact, for papers by Zhenzhou Shen Breakdown of academic impact, for papers by Eugen Ruckhaeberle Breakdown of academic impact, for papers by Angel Rodriguez Breakdown of academic impact, for papers by Antonio Marchetti
Rankless by CCL
2026